Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 14/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 11/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25966750 | 0.87 | HASPIN (0.35) | HASPINLATS1LATS2TBXAS1KDM4C | |
| SCHEMBL25966728 | 0.78 | KAT2B (0.35) | LATS1LATS2KDM4CDYRK1A | |
| SCHEMBL25966752 | 0.78 | MPO (0.45) | — | |
| SCHEMBL25968045 | 0.77 | LATS1 (0.34) | LATS1LATS2KDM4CKCNH2DYRK1A | |
| SCHEMBL25979766 | 0.68 | HTR2A (0.35) | LATS1LATS2HTR2CKCNH2DYRK1A | |
| SCHEMBL25966751 | 0.68 | TLR8 (0.35) | HTR2C | |
| SCHEMBL25966746 | 0.68 | HTR2C (0.35) | TBXAS1HTR2C | |
| SCHEMBL15341875 | 0.65 | ADORA3 (0.38) | KDM4CHTR2CKCNH2DYRK1A | |
| SCHEMBL23046376 | 0.64 | HTR2A (0.34) | HASPINLATS1LATS2HTR2CKCNH2 | |
| SCHEMBL23229478 | 0.63 | DYRK1A (0.36) | HASPINLATS1HTR2CKCNH2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HASPIN 1911/4885LATS1 3117/4885LATS2 3256/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HASPIN 1950/4885LATS1 3097/4885LATS2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.